Antimetastatic Mechanisms of Bisdioxopiperazine Compound Study, A Gateway to Success
Received Date: Aug 15, 2017 / Accepted Date: Aug 20, 2017 / Published Date: Aug 30, 2017
Abstract
Neoplasm metastasis is the causality of 90% cancer patient’s mortality. Bisdioxopiperazine compounds (Biz compounds) are a series of synthetic agents that are firstly discovered to exhibit antimetastatic efficacy to animal tumor models. In order to completely overcome neoplasm metastasis in clinics, antimetastatic therapeutic study for Biz compounds is of great clinical significance. This editorial highlights these researches from new perspective.
Keywords: Bisdioxopiperazine compounds; Probimane; Razoxane; MST-16; Antimetastatic drugs; Neoplasm metastasis; Drug combinations, Drug development
Citation: Lu DY, Ding J, Chen RT, Xu H, Yarla NS, et al. (2017) Antimetastatic Mechanisms of Bisdioxopiperazine Compound Study, A Gateway to Success. J Cell Mol Pharmacol 1: e101.
Copyright: © 2017 Lu DY, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Share This Article
Recommended Journals
Open Access Journals
Article Usage
- Total views: 2682
- [From(publication date): 0-2017 - Nov 18, 2024]
- Breakdown by view type
- HTML page views: 2004
- PDF downloads: 678
